These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 30282064)

  • 1. Phenotypic variations in carriers of predicted protein-truncating genetic variants in MYBPC3: an autopsy-based case series.
    Williams N; Marion R; McDonald TV; Wang D; Zhou B; Eng LS; Um SY; Lin Y; Ruiter K; Rojas L; Sampson BA; Tang Y
    Cardiovasc Pathol; 2018; 37():30-33. PubMed ID: 30282064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of variants in MYH7, MYBPC3 and TNNT2 with sudden cardiac death-related risk factors in Brazilian patients with hypertrophic cardiomyopathy.
    Mori AA; Castro LR; Bortolin RH; Bastos GM; Oliveira VF; Ferreira GM; Hirata TDC; Fajardo CM; Sampaio MF; Moreira DAR; Pachón-Mateos JC; Correia EB; Sousa AGMR; Brión M; Carracedo A; Hirata RDC; Hirata MH
    Forensic Sci Int Genet; 2021 May; 52():102478. PubMed ID: 33588347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A founder MYBPC3 mutation results in HCM with a high risk of sudden death after the fourth decade of life.
    Calore C; De Bortoli M; Romualdi C; Lorenzon A; Angelini A; Basso C; Thiene G; Iliceto S; Rampazzo A; Melacini P
    J Med Genet; 2015 May; 52(5):338-47. PubMed ID: 25740977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic predictive value of gene mutations in Japanese patients with hypertrophic cardiomyopathy.
    Chida A; Inai K; Sato H; Shimada E; Nishizawa T; Shimada M; Furutani M; Furutani Y; Kawamura Y; Sugimoto M; Ishihara J; Fujiwara M; Soga T; Kawana M; Fuji S; Tateno S; Kuraishi K; Kogaki S; Nishimura M; Ayusawa M; Ichida F; Yamazawa H; Matsuoka R; Nonoyama S; Nakanishi T
    Heart Vessels; 2017 Jun; 32(6):700-707. PubMed ID: 27885498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypertrophic cardiomyopathy in myosin-binding protein C (
    Adalsteinsdottir B; Burke M; Maron BJ; Danielsen R; Lopez B; Diez J; Jarolim P; Seidman J; Seidman CE; Ho CY; Gunnarsson GT
    Open Heart; 2020; 7(1):e001220. PubMed ID: 32341788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the effects of a truncating and a missense MYBPC3 mutation on contractile parameters of engineered heart tissue.
    Wijnker PJ; Friedrich FW; Dutsch A; Reischmann S; Eder A; Mannhardt I; Mearini G; Eschenhagen T; van der Velden J; Carrier L
    J Mol Cell Cardiol; 2016 Aug; 97():82-92. PubMed ID: 27108529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel mutation in the cardiac myosin-binding protein C gene is responsible for hypertrophic cardiomyopathy with severe ventricular hypertrophy and sudden death.
    Konno T; Shimizu M; Ino H; Fujino N; Uchiyama K; Mabuchi T; Sakata K; Kaneda T; Fujita T; Masuta E; Mabuchi H
    Clin Sci (Lond); 2006 Jan; 110(1):125-31. PubMed ID: 16181148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease penetrance and risk stratification for sudden cardiac death in asymptomatic hypertrophic cardiomyopathy mutation carriers.
    Michels M; Soliman OI; Phefferkorn J; Hoedemaekers YM; Kofflard MJ; Dooijes D; Majoor-Krakauer D; Ten Cate FJ
    Eur Heart J; 2009 Nov; 30(21):2593-8. PubMed ID: 19666645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenotype-driven molecular autopsy for sudden cardiac death.
    Cann F; Corbett M; O'Sullivan D; Tennant S; Hailey H; Grieve JH; Broadhurst P; Rankin R; Dean JC
    Clin Genet; 2017 Jan; 91(1):22-29. PubMed ID: 27000522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary Myocardial Fibrosis as an Alternative Phenotype Pathway of Inherited Cardiac Structural Disorders.
    Junttila MJ; Holmström L; Pylkäs K; Mantere T; Kaikkonen K; Porvari K; Kortelainen ML; Pakanen L; Kerkelä R; Myerburg RJ; Huikuri HV
    Circulation; 2018 Jun; 137(25):2716-2726. PubMed ID: 29915098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypertrophic cardiomyopathy in a Portuguese population: mutations in the myosin-binding protein C gene.
    Cardim N; Perrot A; Santos S; Morgado P; Pádua M; Ferreira S; Reis RP; Monteiro C; Ferreira T; Correia JM; Osterziel KJ
    Rev Port Cardiol; 2005 Dec; 24(12):1463-76. PubMed ID: 16566405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nationwide study on hypertrophic cardiomyopathy in Iceland: evidence of a MYBPC3 founder mutation.
    Adalsteinsdottir B; Teekakirikul P; Maron BJ; Burke MA; Gudbjartsson DF; Holm H; Stefansson K; DePalma SR; Mazaika E; McDonough B; Danielsen R; Seidman JG; Seidman CE; Gunnarsson GT
    Circulation; 2014 Sep; 130(14):1158-67. PubMed ID: 25078086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Founder mutation in myosin-binding protein C with an early onset and a high penetrance in males.
    Méndez I; Fernández AI; Espinosa MÁ; Cuenca S; Lorca R; Rodríguez JF; Tamargo M; García-Montero M; Gómez C; Vilches S; Vázquez N; Álvarez R; Medrano C; Yotti R; Fernández-Avilés F; Bermejo J
    Open Heart; 2021 Sep; 8(2):. PubMed ID: 34588271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variable cardiac myosin binding protein-C expression in the myofilaments due to MYBPC3 mutations in hypertrophic cardiomyopathy.
    Parbhudayal RY; Garra AR; Götte MJW; Michels M; Pei J; Harakalova M; Asselbergs FW; van Rossum AC; van der Velden J; Kuster DWD
    J Mol Cell Cardiol; 2018 Oct; 123():59-63. PubMed ID: 30170119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spatial and Functional Distribution of
    Helms AS; Thompson AD; Glazier AA; Hafeez N; Kabani S; Rodriguez J; Yob JM; Woolcock H; Mazzarotto F; Lakdawala NK; Wittekind SG; Pereira AC; Jacoby DL; Colan SD; Ashley EA; Saberi S; Ware JS; Ingles J; Semsarian C; Michels M; Olivotto I; Ho CY; Day SM
    Circ Genom Precis Med; 2020 Oct; 13(5):396-405. PubMed ID: 32841044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Novel Founder Mutation in MYBPC3: Phenotypic Comparison With the Most Prevalent MYBPC3 Mutation in Spain.
    Sabater-Molina M; Saura D; García-Molina Sáez E; González-Carrillo J; Polo L; Pérez-Sánchez I; Olmo MDC; Oliva-Sandoval MJ; Barriales-Villa R; Carbonell P; Pascual-Figal D; Gimeno JR
    Rev Esp Cardiol (Engl Ed); 2017 Feb; 70(2):105-114. PubMed ID: 28029522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spectrum of clinical phenotypes and gene variants in cardiac myosin-binding protein C mutation carriers with hypertrophic cardiomyopathy.
    Erdmann J; Raible J; Maki-Abadi J; Hummel M; Hammann J; Wollnik B; Frantz E; Fleck E; Hetzer R; Regitz-Zagrosek V
    J Am Coll Cardiol; 2001 Aug; 38(2):322-30. PubMed ID: 11499719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A rare cause of sudden unexpected death syndrome (SUDS) in the first year of life: endomyocardial fibroelastosis (EFE) due to two compound heterozygous MYBPC3 mutations.
    Hartung B; Tank A; Dittmann S; Ritz-Timme S; Schulze-Bahr E
    BMC Cardiovasc Disord; 2021 Apr; 21(1):174. PubMed ID: 33849460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypertrophic cardiomyopathy clinical phenotype is independent of gene mutation and mutation dosage.
    Viswanathan SK; Sanders HK; McNamara JW; Jagadeesan A; Jahangir A; Tajik AJ; Sadayappan S
    PLoS One; 2017; 12(11):e0187948. PubMed ID: 29121657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy.
    Van Driest SL; Vasile VC; Ommen SR; Will ML; Tajik AJ; Gersh BJ; Ackerman MJ
    J Am Coll Cardiol; 2004 Nov; 44(9):1903-10. PubMed ID: 15519027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.